Galectin-3 contributes to cisplatin-induced myeloid derived suppressor cells (MDSCs) recruitment in Lewis lung cancer-bearing mice

Regulation of Alternative Macrophage Activation by Galectin-3

(2014) A. C. MacKinnon et al.   JOURNAL OF IMMUNOLOGY

Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance

(2012) Elizabeth S. Nakasone et al.   CANCER CELL

The tumor microenvironment is a dominant force in multidrug resistance

(2012) Ana Luísa Correia et al.   DRUG RESISTANCE UPDATES

Tumor-Expressed Inducible Nitric Oxide Synthase Controls Induction of Functional Myeloid-Derived Suppressor Cells through Modulation of Vascular Endothelial Growth Factor Release

(2012) P. Jayaraman et al.   JOURNAL OF IMMUNOLOGY

Cyclophosphamide Promotes Chronic Inflammation–Dependent Immunosuppression and Prevents Antitumor Response in Melanoma

(2012) Alexandra Sevko et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells

(2012) Chun-Te Wu et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Recent advances on the role of tumor exosomes in immunosuppression and disease progression

(2012) Paola Filipazzi et al.   SEMINARS IN CANCER BIOLOGY

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

(2011) Rachel F. Gabitass et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment

(2011) N. Obermajer et al.   CANCER RESEARCH

Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice

(2011) Tangying Lu et al.   JOURNAL OF CLINICAL INVESTIGATION

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

(2011) David G. DeNardo et al.   Cancer Discovery

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

(2010) K. N. Kodumudi et al.   CLINICAL CANCER RESEARCH

Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients

(2010) Palma A. Iacovazzi et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Galectin-3 Exerts Cytokine-Like Regulatory Actions through the JAK-STAT Pathway

(2010) S.-B. Jeon et al.   JOURNAL OF IMMUNOLOGY

Dynamics of galectin-3 in the nucleus and cytoplasm

(2009) Kevin C. Haudek et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells

(2009) Johanna K. Morales et al.   BREAST CANCER RESEARCH AND TREATMENT

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Multiple Myeloma Bone Marrow Niche

(2009) Grzegorz Basak et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

(2008) C. Marcela Diaz-Montero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma

(2008) Yasunori Matsuda et al.   HEPATOLOGY RESEARCH

Galectin-3 Regulates Integrin α2β1-mediated Adhesion to Collagen-I and -IV

(2008) Jens Friedrichs et al.   JOURNAL OF BIOLOGICAL CHEMISTRY